Malaysiakini
ENBM中文TA
Sign In
Subscribe
  • LifetimeACTIVEINACTIVEEXPIRED
  • Registered on:Renews on:Expires on:
    ACTIVEINACTIVEEXPIRED
  • Subscribe
  • Renew
  • Extend Subscription
  • Settings
  • Contact Support
  • Sign Out
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
Malaysiakini
user
Sign In
Subscribe
ENBM中文TA
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
ENBM中文TA

      ANNOUNCEMENT

      He was the sole candidate proposed for the post during a state committee meeting.

      He was the sole candidate proposed for the post during a state committee meeting.

      Analysis: Can first Covid-19 vaccines bring herd immunity? Experts have doubts
      Malaysiakini
      News
      Analysis: Can first Covid-19 vaccines bring herd immunity? Experts have doubts

      Analysis: Can first Covid-19 vaccines bring herd immunity? Experts have doubts

      ReutersPublished: Nov 18, 2020 11:00 PM | Updated: Nov 22, 2020 8:13 PM

      COVID-19 | Governments and officials are voicing hopes that Covid-19 vaccines could bring "herd immunity", with some calculating that immunising just two-thirds of a population could halt the pandemic disease and help protect whole communities or nations.

      But the concept comes with caveats and big demands of what vaccines might be capable of preventing. Some experts say such expectations are misplaced.

      For a start, figuring out what's needed to achieve herd immunity with Covid-19 vaccines involves a range of factors, several of which are unknown...

      Pfizer ends Covid-19 trial with 95pct efficacy, to seek emergency-use authorisation

      Pfizer ends Covid-19 trial with 95pct efficacy, to seek emergency-use authorisation

      M'sia signs 5-year vaccine R&D and supply deal with China

      M'sia signs 5-year vaccine R&D and supply deal with China

      Sinovac's Covid-19 vaccine induces quick immune response: study

      Sinovac's Covid-19 vaccine induces quick immune response: study

      How two companies sprinted ahead in race for Covid vaccine

      How two companies sprinted ahead in race for Covid vaccine

      Breakthrough Covid-19 vaccine tech could help defeat other diseases

      Breakthrough Covid-19 vaccine tech could help defeat other diseases

      New national immunisation schedule for children

      New national immunisation schedule for children

      • comments0
      • facebook
      • whatsapp
      • x
      • comments0
      • facebook
      • whatsapp
      • x
      Related reports6

      Pfizer ends Covid-19 trial with 95pct efficacy, to seek emergency-use authorisation

      19-11-2020

      M'sia signs 5-year vaccine R&D and supply deal with China

      18-11-2020

      Sinovac's Covid-19 vaccine induces quick immune response: study

      18-11-2020

      How two companies sprinted ahead in race for Covid vaccine

      18-11-2020

      Breakthrough Covid-19 vaccine tech could help defeat other diseases

      17-11-2020

      New national immunisation schedule for children

      17-11-2020
      View Comments0

      Comments0

      By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

      Do's and don'ts when posting comments in Malaysiakini

      TERMS & CONDITIONS

      Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

      REPORT VIOLATORS

      Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

      NOTICE

      Our commenting system is still under development. We have taken note of feedback provided.

      Subscriber-only space:

      Are you a subscriber?

      Sign In

      Not yet a subscriber?

      Subscribe

      3200 characters remaining

      Pending comments0

      Are you sure you want to delete this comment?

      This action cannot be undone.

      Report this comment

      500 characters remaining
      mk-logo
      • whatsapp
      • telegram
      • youtube
      • facebook
      • x
      • instagram
      • tiktok
      • linkedin
      • About Us
      • Our Team
      • Privacy Policy
      • Terms of Service
      • Advertise with Us
      • Careers
      • Archive
      • Digital Network
      • KiniTV
      • FG Media
      • RSS Feeds
      • News
      • Opinion
      • Letters
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+6017-323 0707
      envelopesubscribe@malaysiakini.com
      • Advertising
      • advertise@malaysiakini.com
      • advertise@fgmedia.my
      Mkini Dotcom Sdn Bhd
      (199901014818 / 489718-U)No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+603-7770 0017
      envelopesubscribe@malaysiakini.com
      @Kini
      No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor